For Patients with Metastatic Castration-Adsistant Prostate Cancer (MCRPC) Unselected for Homologous Recombination Repair (HRR) GENE Alterrations, Talazoparib (Tala) + ENZALUTAMIDE (Enzalutamide) Associateed with improved overall survival versus placebo + enza, according to a study presented at the American Society of Clinical Oncology Annual Genitourinary Cancers SymposiumHeld from Feb. 13 to 15 in San Francisco.

Neeraj Agarwal, MD, from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and Colleagues Reported Final Overall Surral (OS) Data Among Patients with McRPC UNSELECTED FORRR Gene alterations who had improved radiographic Progression-free survival with tala + enza versus placebo + enZa as first-line treatment in the Phase 3 Talapro-2 Trial.

A Total of 805 Patients were randomly assigned: 402 and 403 to tala + enza and placebo + enza, respectively. At the data cutoff (Sept. 3, 2024), 52 and 60% of Patients in the Tala + Enza and Placebo + Enza Arms, Respectively, Had Died. The Researchers found that the hazard ratio for os was 0.796 (95% Confidence Interval, 0.661 to 0.958) for tala + enza versus placebo + enza, with a media OS of 45.8 and 37.0 months, Respatively.

In Patients Who Were Hrr-Deficient and in that who was we WHO WHO WHO WHO WHO WHO WHO WHO 0.826) And 0.878 (95% Confidence Interval, 0.713 to 1.080), Respected.

Updated radiographic Progression-Free Survival Data Favored Tala + Enza Versus Placebo + Enza, Consistent with the Primary Analysis (hazard ratio, 0.67; 95% CONFIEDENCE Internval, 0.551 to 0.551 to 0.677; 0.807).

“Tala + Enza Demonstrated A Statistically Significant and Clinically Meaningful Improvement in OS Versus Standard-Of-Care Enza,” The Author’s write.

Copyright © 2025 HealthdayAll rights reserved.